Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
66.5M
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
53.6M
-
Shares change
-
+90.9K
-
Total reported value, excl. options
-
$105M
-
Value change
-
+$3.11M
-
Put/Call ratio
-
0.04
-
Number of buys
-
30
-
Number of sells
-
-34
-
Price
-
$1.75
Significant Holders of Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) as of Q1 2025
85 filings reported holding RGLS - Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share as of Q1 2025.
Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.6M shares
of 66.5M outstanding shares and own 80.59% of the company stock.
Largest 10 shareholders include FEDERATED HERMES, INC. (15.8M shares), NEA Management Company, LLC (6.47M shares), Octagon Capital Advisors LP (4.64M shares), BlackRock, Inc. (4.17M shares), VANGUARD GROUP INC (3.95M shares), Deep Track Capital, LP (3.26M shares), Vivo Capital, LLC (2.7M shares), BAKER BROS. ADVISORS LP (2.69M shares), Point72 Asset Management, L.P. (1.97M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.3M shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.